Acromegaly Combination Treatment Study

Phase

TERMINATED

Status

Enrollment

OTHER

Sponsor class

Stopped Review of the 12-month data showed patients who deviated from protocol with full IRB monitoring and reporting could not be optimally analyzed. Reopening the study for new enrollment is not feasible and the study was terminated with IRB approval.

Conditions

Acromegaly

Interventions

DRUG: Pegvisomant
DRUG: Octreotide LAR
DRUG: Lanreotide

Sponsor

Cedars-Sinai Medical Center